Alprazolam Extended-release Tablets
Marketed by:
Barr Laboratories Inc
(Woodcliff Lake, NJ), a
subsidiary of Barr Pharmaceuticals Inc
Compared to:
Xanax XR (Pfizer Inc)
Indication:
August 1, 2006—Barr announced that it received final
approval from the FDA for its application to manufacture
and market alprazolam extended-release tablets,
0.5, 1, 2, and 3 mg. These tablets are indicated for the
treatment of panic disorder, with or without agoraphobia.
Dosage Form:
Tablets: 0.5, 1, 2, and 3 mg
For More Information:
www.barrlabs.com
800-BARRLAB (800-227-7522)
Furosemide Tablets
Marketed by:
Ranbaxy Laboratories Ltd
(Guragon, India)
Compared to:
Lasix Tablets (Aventis
Pharmaceuticals Inc)
Indication:
September 21, 2006—The FDA granted approval to
Ranbaxy to manufacture and market furosemide
tablets, USP, 20, 40, and 80 mg. The FDA has determined
them to be bioequivalent and to have the
same therapeutic effect as the reference drug, Lasix.
These tablets are indicated in adults, infants, and children
for the treatment of edema with congestive
heart failure, liver cirrhosis, and renal disease.
Dosage Form:
Tablets: 20, 40, and 80 mg
For More Information:
www.ranbaxy.com
Simvastatin Tablets
Marketed by:
Teva
Pharmaceuticals
(North Wales, Pa)
Compared to:
Zocor (Merck & Co Inc)
Indication:
June 27, 2006—Teva Pharmaceuticals announced the
introduction and availability of simvastatin tablets,
which are AB-rated and bioequivalent to Zocor tablets.
These tablets are indicated to reduce elevated total
cholesterol, low-density lipoprotein cholesterol, Apo B,
and triglycerides, and to increase high-density lipoprotein
cholesterol in patients with primary hypercholesterolemia
and mixed dyslipidemia.
Dosage Form:
Tablets: 5, 10, 20, and 40 mg
For More Information:
www.tevausa.com
888-TEVA-USA (838-2872)
Topiramate Tablets
Marketed by:
Mylan Laboratories (Pittsburgh, Pa)
Compared to:
Topamax (Ortho-McNeil)
Indication:
September 12, 2006—Mylan Laboratories announced
that it received final approval from the FDA for topiramate
tablets, 25, 100, and 200 mg. Topiramate tablets
are indicated as initial monotherapy in patients 10
years of age and older with partial-onset or primary
generalized tonic-clonic seizures.
Dosage Form:
Tablets: 25, 100, and 200 mg
For More Information:
www.mylan.com
Triamcinolone Acetonide Ointment
Marketed by:
Perrigo Co (Allegan, Mich)
Indication:
September 13, 2006—Perrigo Co announced it will
launch triamcinolone acetonide ointment with a new
Perrigo brand design and new national drug code (NDC)
numbers for 2 strengths. The NDC number for triamcinolone
acetonide ointment 0.025%, 80 g, was 0414-
0054-36 and is now 45802-054-36, and the NDC number
for triamcinolone acetonide ointment 0.1%, 1 lb,
was 0414-0055-05 and is now 45802-055-05. The product
is a topical cortico-steroid used for the relief of the
inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage Form:
Ointment: 0.025%, 15-, 80-, and 454-g tubes; 0.1%, 15-,
80-, and 454-g tubes; 0.5%, 15-g tubes
For More Information:
www.perrigo.com
